Abstract
The ubiquitin E3 ligase substrate adapter cereblon (CRBN) is a target of thalidomide and lenalidomide1, therapeutic agents used in the treatment of haematopoietic malignancies2,3,4 and as ligands for targeted protein degradation5,6,7. These agents are proposed to mimic a naturally occurring degron; however, the structural motif recognized by the thalidomide-binding domain of CRBN remains unknown. Here we report that C-terminal cyclic imides, post-translational modifications that arise from intramolecular cyclization of glutamine or asparagine residues, are physiological degrons on substrates for CRBN. Dipeptides bearing the C-terminal cyclic imide degron substitute for thalidomide when embedded within bifunctional chemical degraders. Addition of the degron to the C terminus of proteins induces CRBN-dependent ubiquitination and degradation in vitro and in cells. C-terminal cyclic imides form adventitiously on physiologically relevant timescales throughout the human proteome to afford a degron that is endogenously recognized and removed by CRBN. The discovery of the C-terminal cyclic imide degron defines a regulatory process that may affect the physiological function and therapeutic engagement of CRBN.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
All data generated or analysed during this study are available in the main text or the Supplementary Information. Uncropped, full western blot images and gels are provided in Supplementary Figs. 6–12. Proteomics data have been deposited to the PRIDE repository with the dataset identifiers PXD025413, PXD030091 and PXD034248. Source data are provided with this paper.
Change history
31 October 2022
In the version of this article initially published, Alessio Ciulli was missing an acknowledgement as a peer reviewer, and has now been included in the HTML and PDF versions of the article.
References
Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345–1350 (2010).
Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301–305 (2014).
Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science 343, 305–309 (2014).
Krönke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 523, 183–188 (2015).
Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376–1381 (2015).
Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755–763 (2015).
Nowak, R. P. et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat. Chem. Biol. 14, 706–714 (2018).
Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane radial ray syndrome. eLife 7, e38430 (2018).
Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. 14, 981–987 (2018).
Asatsuma-Okumura, T. et al. p63 is a cereblon substrate involved in thalidomide teratogenicity. Nat. Chem. Biol. 15, 1077–1084 (2019).
Lupas, A. N., Zhu, H. & Korycinski, M. The thalidomide-binding domain of cereblon defines the CULT domain family and is a new member of the β-tent fold. PLoS Comput. Biol. 11, e1004023 (2015).
Higgins, J. J., Pucilowska, J., Lombardi, R. Q. & Rooney, J. P. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 63, 1927–1931 (2004).
Bachmair, A., Finley, D. & Varshavsky, A. In vivo half-life of a protein is a function of its amino-terminal residue. Science 234, 179–186 (1986).
Koren, I. et al. The eukaryotic proteome is shaped by E3 ubiquitin ligases targeting C-terminal degrons. Cell 173, 1622–1635.e1614 (2018).
Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999).
Gray, W. M., Kepinski, S., Rouse, D., Leyser, O. & Estelle, M. Auxin regulates SCF(TIR1)-dependent degradation of AUX/IAA proteins. Nature 414, 271–276 (2001).
Fischer, E. S. et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49–53 (2014).
Del Prete, D., Rice, R. C., Rajadhyaksha, A. M. & D’Adamio, L. Amyloid precursor protein (APP) may act as a substrate and a recognition unit for CRL4CRBN and Stub1 E3 ligases facilitating ubiquitination of proteins involved in presynaptic functions and neurodegeneration. J. Biol. Chem. 291, 17209–17227 (2016).
Chamberlain, P. P. et al. Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21, 803–809 (2014).
Hartmann, M. D. et al. Thalidomide mimics uridine binding to an aromatic cage in cereblon. J. Struct. Biol. 188, 225–232 (2014).
Boichenko, I., Deiss, S., Bar, K., Hartmann, M. D. & Hernandez Alvarez, B. A FRET-based assay for the identification and characterization of cereblon ligands. J. Med. Chem. 59, 770–774 (2016).
Schilling, S. et al. Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer’s disease-like pathology. Nat. Med. 14, 1106–1111 (2008).
Geiger, T. & Clarke, S. Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides. Succinimide-linked reactions that contribute to protein degradation. J. Biol. Chem. 262, 785–794 (1987).
Voorter, C. E., de Haard-Hoekman, W. A., van den Oetelaar, P. J., Bloemendal, H. & de Jong, W. W. Spontaneous peptide bond cleavage in aging alpha-crystallin through a succinimide intermediate. J. Biol. Chem. 263, 19020–19023 (1988).
Tyler-Cross, R. & Schirch, V. Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. J. Biol. Chem. 266, 22549–22556 (1991).
Brennan, T. V. & Clarke, S. Effect of adjacent histidine and cysteine residues on the spontaneous degradation of asparaginyl- and aspartyl-containing peptides. Int. J. Pept. Protein Res. 45, 547–553 (1995).
Paulus, H. Protein splicing and related forms of protein autoprocessing. Annu. Rev. Biochem. 69, 447–496 (2000).
Mills, K. V., Manning, J. S., Garcia, A. M. & Wuerdeman, L. A. Protein splicing of a Pyrococcus abyssi intein with a C-terminal glutamine. J. Biol. Chem. 279, 20685–20691 (2004).
Shah, N. H. & Muir, T. W. Inteins: natur’s gift to protein chemists. Chem. Sci. 5, 446–461 (2014).
Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98, 8554–8559 (2001).
Van Nguyen, T. et al. Glutamine triggers acetylation-dependent degradation of glutamine synthetase via the thalidomide receptor cereblon. Mol. Cell 61, 809–820 (2016).
Smith, B. E. et al. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat. Commun. 10, 131 (2019).
Lin, Z. et al. Development of photolenalidomide for cellular target identification. J. Am. Chem. Soc. 144, 606–614 (2022).
Sievers, Q. L. et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science 362, eaat0572 (2018).
Li, M. et al. Discovery and characterization of a peptide that enhances endosomal escape of delivered proteins in vitro and in vivo. J. Am. Chem. Soc. 137, 14084–14093 (2015).
Jiang, B. et al. Development of dual and selective degraders of cyclin-dependent kinases 4 and 6. Angew. Chem. Int. Ed. 58, 6321–6326 (2019).
Zhang, B. et al. Proteogenomic characterization of human colon and rectal cancer. Nature 513, 382–387 (2014).
Mertins, P. et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55–62 (2016).
Chen, T. W. et al. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nat. Commun. 8, 465 (2017).
Clark, D. J. et al. Evaluation of NCI-7 cell line panel as a reference material for clinical proteomics. J. Proteome Res. 17, 2205–2215 (2018).
Gao, Q. et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 179, 561–577.e522 (2019).
Clark, D. J. et al. Integrated proteogenomic characterization of clear cell renal cell carcinoma. Cell 179, 964–983.e931 (2019).
Wang, L. B. et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell 39, 509–528 (2021).
Bryk, A. H. & Wisniewski, J. R. Quantitative analysis of human red blood cell proteome. J. Proteome Res. 16, 2752–2761 (2017).
Takata, T., Oxford, J. T., Demeler, B. & Lampi, K. J. Deamidation destabilizes and triggers aggregation of a lens protein, βA3-crystallin. Protein Sci. 17, 1565–1575 (2008).
Wilmarth, P. A. et al. Age-related changes in human crystallins determined from comparative analysis of post-translational modifications in young and aged lens: does deamidation contribute to crystallin insolubility? J. Proteome Res. 5, 2554–2566 (2006).
Kim, E., Lowenson, J. D., MacLaren, D. C., Clarke, S. & Young, S. G. Deficiency of a protein-repair enzyme results in the accumulation of altered proteins, retardation of growth, and fatal seizures in mice. Proc. Natl Acad. Sci. USA 94, 6132–6137 (1997).
Ludwig, K. R., Schroll, M. M. & Hummon, A. B. Comparison of in-solution, FASP, and S-Trap based digestion methods for bottom-up proteomic studies. J. Proteome Res. 17, 2480–2490 (2018).
HaileMariam, M. et al. S-Trap, an ultrafast sample-preparation approach for shotgun proteomics. J. Proteome Res. 17, 2917–2924 (2018).
Huber, W., von Heydebreck, A., Sultmann, H., Poustka, A. & Vingron, M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18, S96–104 (2002).
Chen, I., Dorr, B. M. & Liu, D. R. A general strategy for the evolution of bond-forming enzymes using yeast display. Proc. Natl Acad. Sci. USA 108, 11399–11404 (2011).
Broguiere, N., Formica, F. A., Barreto, G. & Zenobi-Wong, M. Sortase A as a cross-linking enzyme in tissue engineering. Acta Biomater. 77, 182–190 (2018).
Flaxman, H. A., Chang, C. F., Wu, H. Y., Nakamoto, C. H. & Woo, C. M. A binding site hotspot map of the FKBP12–rapamycin–FRB ternary complex by photoaffinity labeling and mass spectrometry-based proteomics. J. Am. Chem. Soc. 141, 11759–11764 (2019).
Popp, M. W., Antos, J. M. & Ploegh, H. L. Site-specific protein labeling via sortase-mediated transpeptidation. Curr. Protoc. Protein Sci. https://doi.org/10.1002/0471140864.ps1503s56 (2009).
Salehi, N. et al. Heme degradation upon production of endogenous hydrogen peroxide via interaction of hemoglobin with sodium dodecyl sulfate. J. Photochem. Photobiol. B 133, 11–17 (2014).
Carbon, J. & Curry, J. B. Genetically and chemically derived missense suppressor transfer RNA’s with altered enzymic aminoacylation rates. J. Mol. Biol. 38, 201–216 (1968).
Acknowledgements
We thank Y. Amako, D. Miyamoto and A. D’Souza for helpful discussions; S. Trager, B. Budnik, R. Robinson and Z. Niziolek for technical support; and the Agilent Center of Excellence in Biomolecular Characterization for instrumentation. His6–CRBN–DDB1 was a gift from Bristol Myers Squibb. Some data used in this publication were generated by the Clinical Proteomic Tumor Analysis Consortium (NCI/NIH). Support from the Ono Pharma Foundation (C.M.W.), Sloan Research Foundation (C.M.W.), Camille–Dreyfus Foundation (C.M.W.), the Blavatnik Biomedical Accelerator at Harvard University (C.M.W.), the National Institutes of Health (R01GM114537, M.R.P.), Japan Society for the Promotion of Science (S.I.) and National Science Foundation (H.A.F.) is gratefully acknowledged.
Author information
Authors and Affiliations
Contributions
S.I., N.V. and D.S. designed and synthesized compounds. S.I. and W.X. designed and performed degradation assays. H.A.F., S.I., W.X. and H.C.L. designed and conducted studies on binary and ternary complex evaluations. H.A.F., H.C.L. and S.I. designed and performed the preparation of degron-bearing proteins and evaluation of the engineered proteins. W.X., H.A.F. and S.I. investigated the formation of cyclic imide PTMs, their destruction via hydrolysis, and their half-lives. W.X., H.A.F., S.I. and H.C.L. prepared samples for proteomics experiments. W.X. designed and performed proteomics experiments, and analysed the proteomics data jointly with C.M.W. B.W. and M.R.P. performed expressed protein ligation. C.M.W. conceived the project and drafted the manuscript. All authors reviewed and edited the manuscript.
Corresponding author
Ethics declarations
Competing interests
Harvard University filed a PCT patent application on 13 April 2022 covering the chemical structures described in this Article and their use. C.M.W., S.I., H.A.F. and W.X. are listed as inventors on this patent. The Woo laboratory receives support from Merck and Ono Pharmaceuticals. All other authors declare no competing interests.
Peer review
Peer review information
Nature thanks Benjamin Cravatt, Alessio Ciulli and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Fig. 1 Examination of bifunctional degraders of BRD4 with candidate degrons for CRBN.
(a) Representative mechanisms of the formation of C-terminal cyclic aspartimide (cN) or glutarimide (cQ) and N-terminal pyroglutamate (pE) in vivo. (b) Structures of JQ1-uracil, JQ1-PEG-uracil, and JQ1-uridine. (c) Western blot of BRD4 after treatment with JQ1-uracil, JQ1-PEG-uracil, JQ1-uridine in HEK293T cells for 24 h. (d) Structures of JQ1-cQ, JQ1-cN, and JQ1-FpE. (e) Western blot of BRD4 after treatment with JQ1-cQ, JQ1-cN, JQ1-FpE in HEK293T cells for 4 h. All western blot data are representative of at least 2 independent replicates. For uncropped western blot images, see Supplementary Fig. 8.
Extended Data Fig. 2 Evaluation of JQ1-XcQ and JQ1-XcN degraders in targeted protein degradation of BRD4.
(a) Western blots of BRD4 levels after treatment of HEK293T cells with 100 nM, 1 µM, or 10 µM dBET6 for the 20 dipeptide degraders. Interestingly, the hook effect resulting in reduced degradation of BRD4 can be observed from dBET6 at 10 µM, but not from the dipeptide degraders. (b) BRD4 degradation with dBET6 over 4 h was competitively inhibited by lenalidomide or Boc-FcQ over a dose-dependent concentration (0.1–100 µM), indicating that the thalidomide-binding domain of CRBN is engaged by glutarimide ligands. (c) Levels of BRD4 over time in HEK293T cells treated with dBET6 or JQ1-FcQ. (d) Evaluation of JQ1-HcN in targeted protein degradation of BRD4 at various concentrations in HEK293T cells over 4 h. This probe was constructed given that protein splicing products (e.g., inteins) are typically promoted by a penultimate histidine. (e) Western blot of BRD4 after treatment of wild type (WT) or shRNA knockdown (CRBN KD) HEK293T cells with the indicated degrader. (f) Western blot of BRD4 after co-treatment of HEK293T cells with JQ1-FcN and lenalidomide or Boc-FcN. (g) Levels of BRD4 over time in HEK293T cells treated with JQ1-FcN. All western blot data are representative of 2 independent replicates. For uncropped western blot images, see Supplementary Fig. 8.
Extended Data Fig. 3 Co-immunoprecipitation and photo-affinity displacement assay with dipeptide degraders and ligands.
(a) Co-immunoprecipitation of endogenous BRD4 from HEK-CRBN in cells (left) or in lysates (right) after 2 h treatment with 25 µM or 1 µM of the indicated degrader. Western blot data are representative of 2 independent replicates. (b) Photo-affinity labeling displacement assay using photo-lenalidomide (pLEN) to visualize in-gel fluorescence imaging of CRBN/DDB1. Comparisons were performed using unpaired two-tailed t-tests. ns = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. Data are presented as mean ± SD (n = 3 biologically independent samples). (c) Structure of photo-lenalidomide (pLEN) and schematic of photo-affinity labeling displacement assay using photo-lenalidomide (pLEN) to visualize in-gel fluorescence imaging of CRBN/DDB1. (d) Corresponding gel images after treatment of CRBN/DDB1 with 1 µM pLEN and 100 µM of the indicated competitor for 30 min prior to photo-affinity labeling and in-gel fluorescence imaging. Data shown include 3 biologically independent replicates. For uncropped western blot and gel images, see Supplementary Fig. 9.
Extended Data Fig. 4 Ternary complex formation of dipeptide ligands with CRBN and BRD4.
(a) Schematic showing the domains of CRBN, including the CULT domain with key residues for immunomodulatory drug binding highlighted, and AlphaScreen design. (b–c) AlphaScreen experiments performed with the indicated degrader compounds. The relative area under the curve reflected the cellular degradation trends, with several of the dipeptide degraders resulting in a signal greater than or comparable to dBET6. Interestingly, the inactive degrader JQ1-cQ promotes ternary complex formation equivalent to the active JQ1-GcQ, indicating that the N–1 amino acid residue positions the ternary complex in a more productive conformation. Data shown in (b) and (c) are each performed on a single 384-well plate; dBET6 was assayed on each plate as an internal control. Each condition was measured in triplicate. (d) Schematic of NanoBRET assay. (e) NanoBRET measurement of ternary complex formation induced by the indicated members of the degrader library as determined by acceptor:donor signal ratio, with background signal from no-ligand control for each degrader subtracted. Each condition was assayed in triplicate. Error bars represent mean ± SEM.
Extended Data Fig. 5 Characterization of the IMiDs and the indicated peptides in HEK293T cells and multiple myeloma MM.1S cells.
(a) Model of dipeptide degraders with CRBN built from 6BOY and 6H0F. Left: Model of JQ1-FcQ (yellow) by molecular modeling of dBET6 (orange) in the ternary complex with CRBN (grey) and BRD4 (blue). Middle: zoom-in of the CRBN binding pocket with thalidomide analog (orange), Ac-FcQ (yellow), or Ac-FcN (green). Right: Model of pomalidomide (orange), FcQ (yellow), and FcN (green) in the ternary complex with CRBN (grey) and IKZF1 (blue, space-filling mode). (b) Structures of Boc-cQ, Me-FcQ, Ac-FcQ, H2N-FcN or H2N-FcQ, Boc-FcN or Boc-FcQ, and GGGFcQ. (c–d) Quantitative proteomics of co-immunoprecipitated proteins from lysates of HEK-CRBN cells overexpressing IKZF1 after 2 h incubation with 1 µM (c) FcN or (d) GGGFcQ. Protein levels were normalized to the amount of CRBN in each channel. P-values for the abundance ratios were calculated by one-way ANOVA with TukeyHSD post-hoc test. (e) Competitive inhibition of BRD4 degradation by the indicated dipeptide degrader (JQ1-FcN, JQ1-FcQ) with the indicated compounds in HEK293T cells for 4 h. All western blot data are representative of 2 independent replicates. (f) Quantitative proteomics of MM.1S cells after treatment with 10 µM of Boc-FcN for 10 h. P-values for the abundance ratios were calculated using the t-test (background) method. (g) Protein expression levels of IKZF1 after treatment with the indicated compounds in MM.1S cells for 10 h. Data are presented as mean ± SD (n = 3 biologically independent samples). (h) Quantitative proteomics of HEK293T cells after treatment with 0.1 µM of JQ1-FcQ or dBET6 for 2 h. P-values for the abundance ratios were calculated using the t-test (background) method. (i) Protein expression levels of BRD2 and BRD4 after treatment with the indicated compounds in HEK293T cells for 2 h. Data are presented as mean ± SD (n = 3 biologically independent samples). All proteomics experiments were performed in biological triplicates. For uncropped western blot images, see Supplementary Fig. 10.
Extended Data Fig. 6 The C-terminal cyclic imide degron is transferrable.
(a-c) Flow cytometry analysis of the GFP levels in (a) HEK293T cells, (b) Jurkat or (c) MEF cells 6 h after electroporation with GFP tagged with the indicated peptide, with or without lenalidomide competition (100 µM). Comparisons were performed using an ordinary one-way ANOVA with Šídák’s multiple comparisons test, and p values are shown above comparison bars. (d) Structure of FKBP12 degraders dFKBP-1 and dFKBP-FcQ. (e) Western blot of FKBP12 levels after treatment of HEK293T cells with dFKBP-1 or dFKBP-FcQ over a 0.1–25 µM dose-response range. (f) Western blot of FKBP12 levels after co-treatment of HEK293T cells with dFKBP-FcQ and lenalidomide or Boc-FcQ. (g) Levels of FKBP12 over time in HEK293T cells treated with dFKBP-1 or dFKBP-FcQ. (h) Structure of CDK6 degraders dCDK6-Pom and dCDK6-FcQ. (i) Western blot of CDK4/6 levels after treatment of Jurkat cells with dCDK6-Pom or dCDK6-FcQ over a 0.01–10 µM dose-response range. (j) Western blot of CDK6 levels after co-treatment of Jurkat cells with dCDK6-FcQ and lenalidomide or Boc-FcQ. (k) Sortase system used to generate degron-tagged GST-FKBP12 from GST-FKBP12-LPETG-His6. (l) In vitro ubiquitination of FKBP12 tagged with C-terminal cyclic imide. FKBP12-H6 = FKBP12 with C-terminal His6 tag (no sortase treatment); FKBP12-Me = FKBP12 with C-terminal FcQMe; FKBP12-FcQ = FKBP12 with C-terminal FcQ; FKBP12-FcN = FKBP12 with C-terminal FcN. (m) Western blot of FKBP12 tagged with the indicated peptides 6 h after electroporation into HEK293T cells. (n) Quantification of Western blot in (m). Error bars represent mean ± SD. Comparisons were performed using an ordinary one-way ANOVA with Šídák’s multiple comparisons test. All western blot data are representative of at least 2 independent replicates. Flow cytometry data is representative of 3 independent replicates. For uncropped western blot images, see Supplementary Fig. 10.
Extended Data Fig. 7 The inteins Npu DnaE and Mtu RecA are not CRBN substrates.
(a) Left: hydrolysis of cyclic imides Fmoc-GGGFcQ or Fmoc-GGGFcN in PBS at 37 °C. (n = 3 biologically independent samples, error bars, which fall within symbols, represent mean ± SD). Right: hydrolysis of C-terminal cyclic imides on GFP-FcQ or GFP-FcN in PBS at 37 °C (n = 3 biologically independent samples, error bars, which fall within symbols, represent mean ± SD). (b) Schematic of the intein splicing mechanism with the penultimate step in intein excision that generates a C-terminal aspartimide highlighted, and the two intein constructs before and after splicing. X = O or S, R = H or CH3. (c) Analysis of expression and splicing of Npu DnaE in E. coli with and without a V5 tag inserted in the intein. (n = 1 biologically independent replicate) (d) In vitro ubiquitination of V5-tagged cell lysate generated in c (n = 3 biologically independent replicates, all shown). (e, f) Effect of MLN4924 or lenalidomide pretreatment on 4-hydroxytamoxifen (4-HT)–induced splicing of GFP with HA-tagged Mtu RecA intein in HEK293T cells. For both e and f, data shown are representative of 2 biologically independent replicates. For uncropped western blot images, see Supplementary Fig. 11.
Extended Data Fig. 8 Analysis of C-terminal cQ/cN modifications on hemoglobin derived from red blood cells and beta-crystallin derived from bovine lens.
(a) Unique proteins and peptides that carry a semi-tryptic terminal N or Q from global proteomics datasets. (b) Western blot of red blood cell (RBC) lysates from two donors in comparison to HEK293T lysate. RBCs do not express CRBN. (c) Representative MS2 spectra of HBB(42–cN58) and HBA(63–cN79) detected in RBC lysates. Western blot is representative of 2 independent replicates. (d) Comparison of peptide spectral matches (PSMs) for selected hemoglobin subunits and actin observed in global proteomics datasets, recombinant hemoglobin beta (HBB) protein, and red blood cell (RBC) lysates. HBA(63–cN69) was observed by extracted ion chromatogram in the MS1. Sites selected for further analysis are highlighted in red or blue. (e) Quantification of the three major peptide groups bearing a C-terminal cyclic imide from RBC samples with or without base treatment. Data are presented as mean ± SD (n = 3 biologically independent samples). The noted p-values were obtained by one-way ANOVA with TukeyHSD post-hoc test from Proteome Discoverer. (f) Quantification of the two major chymotryptic peptide groups bearing C-terminal cyclic imides in RBC samples with or without base treatment. Data are presented as mean ± SD (n = 5 biologically independent samples). The noted p-values were obtained by one-way ANOVA with TukeyHSD post-hoc test from Proteome Discoverer. (g) Quantification of the absolute masses and percentages of HBB(42–60), HBB(42–cN58), and HBB(42–N58) in RBC samples using selected ion monitoring. (h) Ion intensity chromatograms extracted for the masses of the cyclic imide fragment and the corresponding tryptic peptide for three cyclic imide-bearing peptide groups identified in bovine lens. (i) Quantification of these peptide groups validates the sensitivity of the cyclic imide modifications to base treatment. Data are presented as mean ± SD (n = 4 biologically independent samples). The noted p-values were obtained by one-way ANOVA with TukeyHSD post-hoc test from Proteome Discoverer. For uncropped western blot images, see Supplementary Fig. 11.
Extended Data Fig. 9 Analysis of C-terminal cQ/cN and Q/N modifications on synthetic peptides.
(a) Scheme of cyclic imide formation in a peptide and subsequent hydrolysis to afford the truncated C-terminal glutamine or asparagine fragments. (b) Overlay of representative extracted ion chromatograms of each peptide at the masses corresponding to parent peptide (black), cyclic imide fragment (red), and its hydrolyzed products (blue). The two constitutional isomers formed via hydrolysis of the cyclic imide fragment were not distinguished in our study. (c–d) In vitro time course for formation of the cyclic imide fragment and the hydrolysis products at the indicated position on the synthetic peptide after incubation. (e) Percentage of the formed cyclic imide fragment and the hydrolysis products at the indicated residue relative to the parent synthetic peptide at different pH. (f) Ion intensity chromatogram extracted for the masses of the corresponding species for RBC lysates and the mixture of isotopically labeled HBB(42*–60) containing the modifications. The RBC samples were spiked with the peptide mixture and ran on the selected ion monitoring mode to validate the overlap of retention times and amplify the signal of selected ions.
Extended Data Fig. 10 Analysis of substrates bearing C-terminal cQ/cN and Q/N modifications in vitro and in cells.
(a) Schematic of expressed protein ligation using HBB(1–129) thioester and Sec-YcQ or Sec-YcQMe to generate HBB(1–cQ132) or HBB(1–Me132). (b) Western blot of in vitro ubiquitination of HBB proteins in triplicate. Unfortunately neither the HBB[1–cQ132] nor recombinant HBB was amenable to electroporation, which precluded our ability to evaluate CRBN-dependent degradation in cells. (c) TMT-based quantification of K-ε-GG sites identified from the in vitro ubiquitination samples using mass spectrometry. Data are presented as mean ± SD (n = 4 technical replicates). Comparisons were performed using unpaired two-tailed t-tests and p-values are noted. (d) Volcano plots of peptide groups bearing C-terminal cyclic imides in WT HEK293T or CRBN CRISPR/Cas9 knockout HEK293T over 48 h. Upregulated proteins at 1% FDR = red, 5% FDR = pink. ACTB(96–cN111) peptide = blue. P-values for the abundance ratios were calculated by one-way ANOVA with TukeyHSD post-hoc test. (e) Volcano plots of peptide groups bearing C-terminal glutamine or asparagine (protein terminus excluded) in WT HEK293T, CRBN KO HEK293T, or HEK293T treated with 200 µM lenalidomide over 48 h. Upregulated peptide groups at 1% FDR = red, 5% FDR = pink, consistent with a model where blockade of degradation of substrates bearing the C-terminal imide allows the modifications to be hydrolyzed. P-values for the abundance ratios were calculated by one-way ANOVA with TukeyHSD post-hoc test. (f) Volcano plots of peptide groups bearing C-terminal glutamine or asparagine (protein terminus excluded) in MM.1S treated with DMSO or 200 µM lenalidomide over 48 h. Upregulated peptide groups at 1% FDR = red, 5% FDR = pink. P-values for the abundance ratios were calculated by one-way ANOVA with TukeyHSD post-hoc test. (g) Ion intensity chromatogram extracted for the masses of the corresponding species for HEK293T lysates and the mixture of isotopically labeled ACTB(96*–113) containing the modifications. The cell samples were spiked with the peptide mixture and ran on the selected ion monitoring mode to validate the overlap of retention times and amplify the signal of selected ions. For uncropped western blot images, see Supplementary Fig. 11.
Supplementary information
Supplementary Information
This file contains Supplementary Figures 1 to 12, Materials and Instrumentation, Synthetic Procedures, References, NMR Spectra, and IR Spectra.
Supplementary Table 1
Proteins co-immunoprecipitated with Flag–CRBN in presence of pomalidomide or cQ/cN peptides (shown in Figures 2b–c and Extended Data Figures 5c–d). P-values for the abundance ratios were calculated by one-way ANOVA with Tukey’s HSD post hoc test.
Supplementary Table 2
Proteins identified from cells treated with IMID- or cQ/cN-bearing compounds (shown in Figure 2d–e and Extended Data Figures 5f, 5h). P-values for the abundance ratios were calculated using the t-test (background) method.
Supplementary Table 3
cQ/cN and Q/N peptides identified from the meta-analysis of CPTAC datasets.
Supplementary Table 4
cQ/cN peptides detected in recombinant protein or tissues (shown in Figure 4d and Extended Data Figures 8e–f, 8i). P-values for the abundance ratios were calculated by one-way ANOVA with Tukey’s HSD post hoc test.
Supplementary Table 5
Quantification of the formation of cyclic imide and hydrolysis products on peptides (shown in Figure 4e and Extended Data Figures 9c–e).
Supplementary Table 6
K-ε-GG peptides identified from HBB in vitro ubiquitination samples (shown in Extended Data Figure 10c). P-values were calculated by unpaired two-tailed t-tests using the shown abundances (the P-values in this table were not used).
Supplementary Table 7
cQ/cN and Q/N peptides identified from HEK293T and MM.1S cells (shown in Figures 5c–d and Extended Data Figures 10d–f). P-values for the abundance ratios were calculated by one-way ANOVA with Tukey’s HSD post hoc test.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ichikawa, S., Flaxman, H.A., Xu, W. et al. The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron. Nature 610, 775–782 (2022). https://doi.org/10.1038/s41586-022-05333-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41586-022-05333-5
This article is cited by
-
Targeted protein degradation: from mechanisms to clinic
Nature Reviews Molecular Cell Biology (2024)
-
Comprehensive assessment of TECENTRIQ® and OPDIVO®: analyzing immunotherapy indications withdrawn in triple-negative breast cancer and hepatocellular carcinoma
Cancer and Metastasis Reviews (2024)
-
Discovery of a Drug-like, Natural Product-Inspired DCAF11 Ligand Chemotype
Nature Communications (2023)
-
Life mimics art
Cell Research (2023)
-
Orphan quality control by an SCF ubiquitin ligase directed to pervasive C-degrons
Nature Communications (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.